115例宫颈鳞癌患者的临床病理特点及治疗后生存分析-东南大学学报医学版

115例宫颈鳞癌患者的临床病理特点及治疗后生存分析

单位：南通市肿瘤医院/南通大学附属肿瘤医院妇科, 江苏南通 226361

分类号：R459.9; R737.33

出版年·卷·期（页码）：2024·43·第一期（71-77）

摘要：

目的: 探讨115例宫颈鳞癌患者的临床病理特点,并进行治疗后生存分析。方法: 回顾性分析2019年1月至12月南通市肿瘤医院收治的115例宫颈鳞癌患者的临床资料,采用SPSS 23.0软件对数据进行统计学分析,采用Kaplan-Meier生存分析法、Log-rank检验、Cox比例风险回归模型进行生存分析及影响因素分析。结果: 115例宫颈鳞癌患者中,72.17%的肿瘤大小≤ 4 cm;52.17%的浸润深度>1/2;95.65%的分化程度为中、低分化;22.61%出现淋巴结转移;32.17%出现淋巴脉管浸润;92.17%无神经侵犯;98.26%无宫旁浸润;所有病例均未出现卵巢转移。3年生存率90.43%,11例死亡。多因素Cox分析结果显示,宫颈鳞癌患者的3年总体生存率与浸润深度、分化程度、是否淋巴结转移、是否淋巴脉管浸润有关(P<0.05)。结论: 115例宫颈鳞癌中、低分化构成比较高,多数肿瘤大小≤ 4 cm,可能出现淋巴结转移、淋巴脉管浸润、神经侵犯,经规范治疗后3年总体生存率尚可。浸润深度、分化程度、是否淋巴结转移、是否淋巴脉管浸润是影响115例宫颈鳞癌患者3年总体生存率的独立因素。

Objective: To investigate the clinicopathological characteristics of 115 cases of cervical squamous cell carcinoma,and to analyze the survival after treatment. Methods: The data of 115 cases of cervical squamous cell carcinoma admitted to the Nantong Tumor Hospital from January 2019 to December 2019 were analyzed retrospectively,SPSS 23.0 software was applied for statistical analysis of the data,Kaplan-Meier survival analysis,Log-rank test and Cox proportional risk regression model were used for survival analysis and influencing factors analysis. Results: Among the 115 cases of cervical squamous cell carcinoma,72.17% of patients had tumors ≤ 4 cm in size; 52.17% of patients had infiltration depth >1/2; 95.65% of patients had moderate to low differentiation; 22.61% of patients had lymph node metastasis; 32.17% of patients had lymphatic vessel infiltration; 92.17% of patients had no nerve invasion; 98.26% of patients had no periuterine infiltration; no ovarian metastasis occurred in all cases. The 3-year survival rate was 90.43%,and 11 cases died. Multivariate Cox analysis showed that the 3-year overall survival rate of patients with cervical squamous cell carcinoma was related to the depth of invasion,degree of differentiation,lymph node metastasis and lymphatic vessel invasion (P<0.05).Conclusion: Most of the 115 patients with cervical squamous cell carcinoma are of medium to low differentiation,with tumors ≤ 4 cm in size and lymph node metastasis,lymphatic vessel invasion and nerve invasion. After standardized treatment,the 3-year overall survival rate is still acceptable. The depth of invasion,degree of differentiation,lymph node metastasis and lymphatic vessel invasion are independent factors affecting the 3-year overall survival rate of 115 patients with cervical squamous cell carcinoma.

参考文献：

[1] SIEGEL R L,MILLER K D,WAGLE N S,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.
[2] 中国抗癌协会妇科肿瘤专业委员会.子宫颈癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):474-489.
[3] 龚敏,刘巧玲.高危型HPV分型定量与宫颈癌相关病变关系研究[J].现代医学,2022,50(4):460-465.
[4] BHATLA N,DENNY L.FIGO cancer report 2018[J].Int J Gynaecol Obstet,2018,143(Suppl 2):2-3.
[5] 李道娟,师金,靳晶,等.宫颈癌的流行病学趋势[J].中华肿瘤杂志,2021,43(9):912-916.
[6] 黄丽色,唐雄志.代谢综合征及其成分与宫颈癌相关性的研究进展[J].现代医学,2023,51(2):280-282.
[7] 张添辉,龙曦,陈思萍,等.基于FIGO2018分期的宫颈癌MRI术前分期与术后病理分期对照研究[J].实用放射学杂志,2022,38(2):278-281,284.
[8] 王旭东,刘羽.HPV E6/E7 mRNA检测在宫颈癌筛查中的价值[J].临床与病理杂志,2022,42(6):1290-1295.
[9] SINGINI M G,SINGH E,BRADSHAW D,et al.Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer:a systematic review and meta-analysis[J].J Med Virol,2023,95(1):e27900.
[10] 程文俊,申庆文.高危型HPV感染者宫颈免疫状况及与宫颈癌的关系[J].分子诊断与治疗杂志,2021,13(5):766-769.
[11] 李婵玉.高危型HPV在宫颈癌发生发展中的作用机制[J].实用癌症杂志,2021,36(3):519-522.
[12] KAMAMOTO S,MURAYAMA A,HAMAKI T,et al.HPV vaccination and cervical cancer screening[J].Lancet,2022,399(10339):1939-1940.
[13] PAULINO E,DE MELO A C,DE ANDRADE D A P,et al.Systemic therapy for advanced cervical cancer:leveraging the historical threshold of overall survival[J].Crit Rev Oncol Hematol,2023,183:103925.
[14] MONK B J,ENOMOTO T,KAST W M,et al.Integration of immunotherapy into treatment of cervical cancer:recent data and ongoing trials[J].Cancer Treat Rev,2022,106:102385.
[15] 林雨璇,孔为民.宫颈癌治疗后生活质量研究方法及进展[J].中国生育健康杂志,2022,33(2):194-197.
[16] CHUAI Y,RIZZUTO I,ZHANG X,et al.Vascular endothelial growth factor (VEGF) targeting therapy for persistent,recurrent,or metastatic cervical cancer[J].Cochrane Database Syst Rev,2021,3(3):CD013348.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录